European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis b surface antigen - hepatitis b; immunization - vaccines - fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients).

European Union - English - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 3.75 microgram - injection, suspension - excipient ingredients: water for injections; polysorbate 80; magnesium chloride hexahydrate; sodium chloride; thiomersal; potassium chloride; dibasic sodium phosphate dodecahydrate; octoxinol 10; monobasic potassium phosphate - prophylaxis of influenza in an officially declared pandemic situation. pandemrix h5n1 should be used in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram - injection, suspension - excipient ingredients: aluminium; dibasic sodium phosphate; calcium chloride dihydrate; potassium chloride; thiomersal; monobasic sodium phosphate; monobasic potassium phosphate; sodium chloride - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with australian health authorities' recommendations, taking into account the recommendation of the world health organisation.

European Union - English - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.nuvaxovid xbb.1.5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - sars-cov-2 rs (nvx-cov2373), quantity: 10 microgram/ml - injection, suspension - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; polysorbate 80; cholesterol; sodium hydroxide; dibasic sodium phosphate heptahydrate; phosphatidyl choline; monobasic potassium phosphate; potassium chloride; quillaja saponaria saponins fraction a; quillaja saponaria saponins fraction c; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - nuvaxovid has approval for the indication: active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 12 years of age and older. the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccines - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: calcium chloride dihydrate; citric acid monohydrate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; monobasic potassium phosphate; polysorbate 80; potassium chloride; sodium chloride; sodium citrate dihydrate; sorbitan trioleate; squalene; water for injections - active immunisation against influenza in persons 65 years of age and older.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - whole virion, inactivated, containing antigen*: a/vietnam/1194/2004 (h5n1)* produced in eggs - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fort dodge australia pty limited - egg drop syndrome virus strain 76 - immunotherapy - poultry layers (eggs for human consump) | poultry pullets (growing chook) | breeding pullets | caged layers | chickens | chooks - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus